益生菌制剂可减少原发性肝癌合并肝硬化患者介入术后并发症的发生

Probiotics reduce complications induced by interventional therapy in patients with primary hepatic carcinoma and liver cirrhosis

目的探讨口服益生菌制剂对原发性肝癌介入治疗后并发症的影响。方法肝硬化合并原发性肝癌患者264例，随机分为试验组和对照组，并给予相同方案的经肝动脉导管灌注化疗栓塞术（TACE）治疗。试验组于介入术前5d起至术后7d内加服益生菌制剂。比较2组患者介入术后近期临床表现、肝功能、血常规及疼痛评分。结果介入术后第3天，试验组腹胀、便秘的发生率明显低于对照组，差异有统计学意义（x^2值分别为18．22和55．22，P值均为0．000）；介入术后第7天，试验组腹胀、便秘和感染的发生率显著低于对照组（x^2值分别为5．35、13．5和19．14，P值分别为0．021、0．000和0．000）；2组在其他临床症状、肝功能、血常规和疼痛评分方面无明显差异。结论口服益生菌制剂可减少患者介入术后部分并发症的发生，有一定的临床应用价值。

Objective To investigate whether oral administration of probiotics can reduce complications induced by interventional therapy in patients with primary hepatic carcinoma and liver cirrosis. Methods Two hundred and sixty four patients with primary hepatic carcinoma and liver cirrhosis who underwent transarterial ehemoembolization （TACE） were randomly divided into two groups, and patients in experimental group were given probiotics but not in control group. Short-term clinical manifestations, liver functions, blood routine and pain scores were compared between two groups. Results On the day 3 after therapy, the incidence of abdominal distension and constipation in experimental group were less than that in control group （x^2 = 18.22 and 55.22, P = 0. 000） ; On the day 7 after therapy, the incidence of abdominal distension, constipation and infection in experimental group were less than that in control group （x^2 = 5.35, 13.5 and 19. 14, P = 0. 021, 0. 000 and 0. 000）. There were no significant difference in other clinical manifestations, liver function, blood routine and pain scores between the two groups. Conclusion Oral administration of probiotics can reduce the incidence of some short-term complication induced by interventional therapy in patients with hepatic carcinoma and liver cirrhosis.